Chelariu-Raicu A, Nick A, Urban R, Gordinier M, et al. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. Gynecol Oncol 2020 Nov 23. pii: S0090-8258(20)34124.
PMID: 33243443